MedTrace Logo

Reduction of Anticholinergic Medications Among Persons With Schizophrenia or Other Psychiatric Disorders

NCT07043803 · Status: ACTIVE_NOT_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 111

Last updated 2026-05-07

No results posted yet for this study

Summary

The goal of this study is to reduce Anticholinergic Medication (ACM) in persons with psychoses or serious mental illness, when these medications are no longer needed.

Conditions

  • Schizophenia Disorder
  • Schizoaffective Disorder
  • Bipolar Disorder
  • Psychiatric Disorders

Interventions

OTHER

Reduction of anticholinergic medication

Shared decision making between the patient and prescriber will determine the timing and speed of reduction over a period of 12 to 16 weeks. Some patients will be discontinued from these anticholinergic medications (benztropine/trihexyphenidyl), others will be tapered from their original dosage but not completely discontinued, and some patients may not be able to taper the anticholinergic medications at all.

Sponsors & Collaborators

  • National Center for Advancing Translational Sciences (NCATS)

    collaborator NIH

  • University of Pittsburgh Medical Center

    collaborator OTHER

  • University of Pittsburgh

    lead OTHER

Principal Investigators

  • Professor of Psychiatry, MD · University of Pittsburgh

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-07-16
Primary Completion
2026-05-31
Completion
2026-05-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07043803 on ClinicalTrials.gov